Mouse Anti-CDKN2A Recombinant Antibody (CBFYC-1641) (CBMAB-C1702-FY)

Name: Mouse Anti-CDKN2A Recombinant Antibody (CBFYC-1641)
SKU: CBMAB-C1702-FY
Rating: 5 (1 reviews)

See all CDKN2A antibodies

Compare Online Inquiry

Published Data

Mouse Anti-CDKN2A Recombinant Antibody (CBFYC-1641) (CBMAB-C1702-FY) in IHC

Immunohistochemical detection of p19Arf, p16Ink4a, p53, and p21Cip1 in mammary glands of MDTG mice.
All of these proteins were induced in MMG from MDTG females suggesting the activation of the p53 and Rb pathways by Dmp1 in vivo. Scale bars show 100 µm. ...View More

Fry, E. A., Taneja, P., Maglic, D., Zhu, S., Sui, G., & Inoue, K. (2013). Dmp1α inhibits HER2/neu-induced mammary tumorigenesis. PLoS One, 8(10), e77870.

Distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

CBFYC-1641

Application

WB, IP, IF, ELISA

Immunogen

Amino acids 1-168 representing full length p16 INK4A of mouse.

Host Species

Mouse

Specificity

Mouse

Antibody Isotype

IgG1

Clonality

Monoclonal Antibody

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Application	Note
WB	1:100-1:1,000
IP	1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)
IF(ICC)	1:50-1:500
ELISA	1:100-1:1,000

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS, 0.1% gelatin

Preservative

< 0.1% sodium azide

Concentration

0.2 mg/ml

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at-20°C long term. Avoid repeated freeze/thaw cycles.

More Infomation

Target

Full Name

Cyclin Dependent Kinase Inhibitor 2A

Introduction

Thus some aberration of the CDKN2A, CDK4 and RB1 genes appears to be almost obligatory in glioblastomas.

Entrez Gene ID

1029

UniProt ID

P42771

Alternative Names

Cyclin Dependent Kinase Inhibitor 2A; Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4); Cyclin-Dependent Kinase 4 Inhibitor A; Cyclin-Dependent Kinase Inhibitor 2A; Multiple Tumor Suppressor 1; Alternative Reading Frame; P16-INK4A; P16INK4A; P14ARF; CDKN2; CDK4I; MTS-1; MTS1; MLM

Function

Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.

Biological Process

Cell cycle arrest Source: BHF-UCL
Cellular senescence Source: BHF-UCL
G1/S transition of mitotic cell cycle Source: BHF-UCL
Negative regulation of cell growth Source: BHF-UCL
Negative regulation of cell-matrix adhesion Source: BHF-UCL
Negative regulation of cell population proliferation Source: BHF-UCL
Negative regulation of cyclin-dependent protein serine/threonine kinase activity Source: BHF-UCL
Negative regulation of G1/S transition of mitotic cell cycle Source: Reactome
Negative regulation of NF-kappaB transcription factor activity Source: BHF-UCL
Negative regulation of phosphorylation Source: BHF-UCL
Negative regulation of transcription, DNA-templated Source: UniProtKB
Positive regulation of cellular senescence Source: UniProtKB
Positive regulation of macrophage apoptotic process Source: BHF-UCL
Positive regulation of smooth muscle cell apoptotic process Source: BHF-UCL
Ras protein signal transduction Source: BHF-UCL
Regulation of transcription initiation from RNA polymerase II promoter Source: Reactome
Replicative senescence Source: BHF-UCL
Senescence-associated heterochromatin focus assembly Source: UniProtKB

Cellular Location

Nucleus; Cytoplasm

Involvement in disease

The association between cutaneous and uveal melanomas in some families suggests that mutations in CDKN2A may account for a proportion of uveal melanomas. However, CDKN2A mutations are rarely found in uveal melanoma patients.
Melanoma, cutaneous malignant 2 (CMM2): A malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites.
Familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC): An inherited cancer predisposition syndrome characterized by an increased risk of developing malignant melanoma and/or pancreatic cancer. Mutation carriers within families may develop either or both types of cancer.
Melanoma-astrocytoma syndrome (MASTS): Characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma.

PTM

Phosphorylation seems to increase interaction with CDK4.

Xu, J., Li, N., Deng, W., & Luo, S. (2021). Discovering the mechanism and involvement of the methylation of cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and its special locus region in gastric cancer. Bioengineered, 12(1), 1286-1298.

Salmani, T., Ghaderian, S. M. H., Hajiesmaeili, M., Mirghaed, O. R., Rakhshan, A., Nasiri, M. J., & Mohammadi, M. (2020). Cyclin dependent kinase inhibitor 2A and miR-671-5p expression profile in Iranian glioblastoma multiforme. Gene Reports, 19, 100620.

Althakfi, W., Gazzo, S., Blanchet, M., Isaac, S., Piaton, E., Villeneuve, L., ... & Brevet, M. (2020). The value of BRCA‐1‐associated protein 1 expression and cyclin‐dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens. Cytopathology, 31(1), 5-11.

Seifi, S., Pouya, F., Rahmani, M., Mehramiz, M., Rastgar‐Moghadam, A., Gharib, M., ... & Avan, A. (2020). Association of cyclin‐dependent kinase inhibitor 2A/B with increased risk of developing breast cancer. Journal of cellular physiology, 235(6), 5141-5145.

Zhang, H. H., Mao, J. S., & Hu, W. F. (2019). Functional genetic single-nucleotide polymorphisms (SNPs) in cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) locus are associated with risk and prognosis of osteosarcoma in chinese populations. Medical science monitor: international medical journal of experimental and clinical research, 25, 1307.

Zhang, W., Kuang, P., & Liu, T. (2019). Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis. Annals of medicine, 51(1), 28-40.

Agarwal, M., Bakhshi, S., Dwivedi, S. N., Kabra, M., Shukla, R., & Seth, R. (2018). Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia. Pediatric blood & cancer, 65(6), e27001.

O'Hara, S. P., Splinter, P. L., Trussoni, C. E., Pisarello, M. J. L., Loarca, L., Splinter, N. S., ... & LaRusso, N. F. (2017). ETS proto-oncogene 1 transcriptionally up-regulates the cholangiocyte senescence-associated protein cyclin-dependent kinase inhibitor 2A. Journal of Biological Chemistry, 292(12), 4833-4846.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-CDKN2A Recombinant Antibody (CBFYC-1641)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Mouse Anti-CDKN2A Recombinant Antibody (CBT2799) (CAT#: V2LY-0625-LY2794)

Mouse Anti-CDKN2A Recombinant Antibody (CBT2041) (CAT#: V2LY-0625-LY91)

Rabbit Anti-CDKN2A Recombinant Antibody (P0206) (CAT#: CBMAB-P0206-YC)

Mouse Anti-CDKN2A Recombinant Antibody (CBFYC-1640) (CAT#: CBMAB-C1701-FY)

Mouse Anti-CDKN2A Recombinant Antibody (CBFYC-1637) (CAT#: CBMAB-C1698-FY)

Mouse Anti-CDKN2A Recombinant Antibody (CBT965) (CAT#: V2LY-0625-LY3142)

Mouse Anti-CDKN2A Recombinant Antibody (CBT3828) (CAT#: V2LY-0625-LY1418)

Mouse Anti-CDKN2A Recombinant Antibody (CBT967) (CAT#: V2LY-0625-LY3140)

Mouse Anti-CDKN2A Recombinant Antibody (1E12E10) (CAT#: CBMAB-C3919-LY)

Mouse Anti-CDKN2A Recombinant Antibody (CBFYC-1638) (CAT#: CBMAB-C1699-FY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry